Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments
Cannabis Law Report
NOVEMBER 15, 2021
–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. We are looking forward to the completion of the required IND enabling studies and submitting our IND package to the FDA in anticipation of first-in-human trials,” continued Mr. Mack. VRP324 represents our first CNS disorder product indication.
Let's personalize your content